<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-ONC-16009421</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2016-10-15</date_registration>
      <primary_sponsor>Hematologic disease center,First Affiliated Hospital of XinJiang Medical University </primary_sponsor>
      <public_title>Research to hematopoiesis and immune reconstruction after reduced-intensity conditioning HLA-haploidentical high dose peripheral blood hematopoietic stem cell transplantation</public_title>
      <acronym />
      <scientific_title>Research to hematopoiesis and immune reconstruction after reduced-intensity conditioning HLA-haploidentical high dose peripheral blood hematopoietic stem cell transplantation</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2016-10-01</date_enrolment>
      <type_enrolment />
      <target_size>Hematopoietic stem cell transplantation group:40;</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=15794</url>
      <study_type>Observational study</study_type>
      <study_design>Case series</study_design>
      <phase>New Treatment Measure Clinical Study</phase>
      <hc_freetext>hematologic malignance</hc_freetext>
      <i_freetext>Hematopoietic stem cell transplantation group:Reduced-intensity conditioning regimen related HLA-haploidentical non T cell-depleted in vitro peripheral hematopoietic stem cell transplantation;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Hongbo Wang</firstname>
        <middlename />
        <lastname />
        <address>8 Liyushan road, Urumuqi, Xinjiang Uygur Autonomous Region, China </address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 15276821839</telephone>
        <email>xjwhb001@sina.com</email>
        <affiliation>Hematologic disease center, First Affiliated Hospital of Xinjiang Medical University </affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Ming Jiang</firstname>
        <middlename />
        <lastname />
        <address>8 Liyushan road, Urumuqi, Xinjiang Uygur Autonomous Region, China </address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 13609910116</telephone>
        <email>jiangmingyy@126.com</email>
        <affiliation>Hematologic disease center, First Affiliated Hospital of Xinjiang Medical University </affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. Patients aged 50 to 65 years old with hematologic malignancies;
2. Patients who is below 50 years old have the fellowing situtation:
1) Patients have an urgent need for transplantation, but with uncured infection. Exp. Patiens have Tuberculosis with residual lesions after anti-TB treatment at 6-9 months, or with standard anti-TB treatment over 3 months; Patiens have remaining infection lesions after infection of bacterial and fungal but stable condition;
2) Organ disfunction: Patients have cardiovascular, respiratory system disease, and dysfunction of liver and kidney who is evaluated to tolerated to RIC-RHNT-PBSCT;
3) Patients can not received MAC transplantation whose bodies are also weaker for some reason.</inclusion_criteria>
      <agemin>14</agemin>
      <agemax>65</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1. Patient who is over 65 years old;
2. Patients who suffer uncontrollable infection;
3. Patiens with severe cardiovascular,respiratory system disease and dysfunction of liver and kidney;
4. Patients with mental disease;
5. Patients who refuse to sign the informed consent.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Engraft rate;Acute graft versus host disease;The cumulative incidence of infection;Costimulatory molecules;Basic immunologic function;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Chronic graft versus host disease;Overall Surviver;Disease free survival;Transplantation related mortality;Relapse rate;</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Natural Science Foundation of China</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2016-03-04</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>